ALX Oncology Q3 net loss narrows as R&D costs drop

ALX Oncology Holdings

07/11/2025 13:23

Overview

ALX Oncology Q3 net loss narrows to $22.1 mln, driven by reduced R&D expenses

Appointed Barbara Klencke, M.D., as interim Chief Medical Officer

Outlook

Company expects cash runway to last into Q1 2027

ALX Oncology anticipates interim data for ASPEN-09 in Q3 2026

Initial safety data for ALX2004 expected in 1H 2026

Result Drivers

R&D EXPENSES - Reduced R&D expenses contributed to a narrower net loss for the quarter

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.41
Q3 Net Income
-$22.14 mln
Q3 Basic EPS
-$0.41
Q3 Income from Operations
-$22.53 mln
Q3 Operating Expenses
$22.53 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $3.00, about 60.7% above its November 6 closing price of $1.18

Press Release: ID:nGNXb38NFx

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)